Specialties – Page 49

Challenging the Compaction Paradigm: Why Endometrial Thinning May Not Predict Pregnancy Success in HRT-FET

By MedXY 12/26/2025

A large-scale analysis of over 16,000 cases reveals that endometrial compaction following progesterone administration does not improve pregnancy outcomes in HRT-FET, and may even be associated with lower success rates in blastocyst transfers.

news OB/GYN & Women's Health

Live Birth Rates Independent of Sex-Steroid Levels in Dydrogesterone-Based Programmed-Ovulatory FET: A Shift in Luteal Support Monitoring?

By MedXY 12/26/2025

A multicentric study demonstrates that sex-steroid levels on the day of embryo transfer do not predict live birth rates in a novel programmed-ovulatory FET protocol using dydrogesterone, suggesting that routine hormonal monitoring may be unnecessary when corpus luteum function is preserved.

Neurology news Pathology & Lab Medicine

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

By MedXY 12/26/2025

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.

news Ophthalmology Rheumatology

Pentosan Polysulfate Maculopathy Following Subcutaneous Injections for Arthritis: A Case Series

By MedXY 12/26/2025

Three cases of pentosan polysulfate maculopathy occurred after subcutaneous administration for arthritis at much lower cumulative doses than oral use, highlighting retinal toxicity risk and need for early detection.

Cardiology news

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood pressure and advanced age, emphasizing the need for vigilant clinical monitoring.

Cardiology news

Nanosecond Pulsed Field Ablation Matches Radiofrequency Efficacy While Slashing Procedure Time: Insights From the InsightPFA Trial

By MedXY 12/26/2025

The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while maintaining a comparable safety profile.

Cardiology news

Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic Cardiomyopathy

By MedXY 12/25/2025

The MAPLE-HCM trial demonstrates that aficamten monotherapy provides superior, rapid, and comprehensive clinical benefits compared to the traditional first-line treatment, metoprolol, across multiple disease domains in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiology Clinical Updates news

Comparative Efficacy, Safety, and Complications of Subcutaneous Versus Transvenous Implantable Cardioverter-Defibrillators: Insights from the PRAETORIAN and ATLAS Trials and Meta-Analyses

By MedXY 12/25/2025

This review synthesizes randomized trial data comparing subcutaneous and transvenous ICDs, highlighting differences in inappropriate shocks, device-related complications, and shock efficacy, underscoring clinical considerations for ICD selection.

Cardiology Internal Medicine news

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

By MedXY 12/25/2025

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI above 35 kg/m2, emphasizing a targeted therapeutic advantage for this high-risk population.

news OB/GYN & Women's Health Psychiatry

Benzodiazepine Exposure and Adverse Pregnancy Outcomes: New Evidence from a Large-Scale Target Trial Emulation

By MedXY 12/25/2025

A large-scale cohort study emulating randomized trials indicates that benzodiazepine use during pregnancy significantly increases the risk of abortion and preterm birth, even after accounting for competing risks and maternal factors. Risks were most pronounced with second-trimester exposure.

Diabetes & Endocrinology news

PCOS as a Biological Model for Reproductive Longevity: Enhanced Ovarian Reserve and ART Success in Aging Asian Women

By MedXY 12/25/2025

A retrospective study of 1,249 Asian women reveals that those with PCOS maintain superior ovarian reserve and stable cumulative pregnancy rates via ART even after age 36, suggesting PCOS may serve as a biological model for extended reproductive longevity.

Cardiology news Public Health

Statin Initiation and Follow-Up Testing Are Declining in Young Adults Despite High Cardiovascular Risk

By MedXY 12/25/2025

A large-scale study of over 700,000 young adults reveals a concerning decline in lipid follow-up and statin initiation between 2008 and 2018, highlighting a critical care gap in preventing premature cardiovascular disease during a key window of vulnerability.

Cardiology news

Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial

By MedXY 12/25/2025

The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of-life improvements for patients with severe aortic stenosis.

Cardiology news

Pulsed Field Ablation Demonstrates Exceptional Safety in Real-World Practice: Insights from the 40,000-Patient MANIFEST-US Study

By MedXY 12/25/2025

The MANIFEST-US study of over 40,000 patients confirms that pulsed field ablation (PFA) for atrial fibrillation maintains a high safety profile in real-world U.S. clinical practice, with a major complication rate of just 0.63% and a complete absence of esophageal fistulas or pulmonary vein stenosis.

Cardiology Infectious Diseases news

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

By MedXY 12/25/2025

The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio suggest biological activity and safety in this neglected population.

Cardiology Neurology news

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

By MedXY 12/25/2025

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk for cognitive impairment and structural brain changes.

Clinical Updates news Urology

Life’s Essential 8 Score and Male Reproductive Health: Insights from the Led-Fertyl Cohort on Sperm Quality

By MedXY 12/25/2025

Higher adherence to the Life's Essential 8 cardiovascular health score is positively linked to improved sperm quality parameters, including count and motility, in reproductive-aged men.

news Public Health

Benchmarking the Ovarian Reserve: New Population-Based Data Reveal Wide Variability in Young Women

By MedXY 12/25/2025

A Norwegian population-based study of 492 women aged 18-22 reveals significant inter-individual variability in ovarian volume, antral follicle count, and AMH levels, providing a critical baseline for understanding reproductive health before the onset of age-related decline.

Cardiology news Oncology

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

By MedXY 12/25/2025

The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratification models in cardio-oncology.

Cardiology news Transplantation

Aggressive LDL-C Lowering Post-Heart Transplant: Why Alirocumab Didn’t Halt Early Vasculopathy in the CAVIAR Trial

By MedXY 12/25/2025

The CAVIAR trial reveals that while alirocumab significantly reduces LDL-C in heart transplant recipients, it does not arrest coronary plaque progression within the first year, suggesting that early cardiac allograft vasculopathy may be driven by non-lipid mechanisms.